Daiwa Securities Group
DRNA

Daiwa Securities Group’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Daiwa Securities Group’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-266
Closed -$5K – 1481
2021
Q3 		$5K Buy
266
+125
+89% +$3.45K ﹤0.01% 1186
2021
Q2 		$5K Hold
141
– – ﹤0.01% 1081
2021
Q1 		$4K Hold
141
– – ﹤0.01% 1096
2020
Q4 		$3K Sell
141
-281
-67% -$6.19K ﹤0.01% 1103
2020
Q3 		$8K Buy
422
+36
+9% +$745 ﹤0.01% 1063
2020
Q2 		$7K Hold
386
– – ﹤0.01% 1092
2020
Q1 		$7K Hold
386
– – ﹤0.01% 1085
2019
Q4 		$9K Sell
386
-50
-11% -$1.01K ﹤0.01% 1077
2019
Q3 		$6K Buy
436
+37
+9% +$529 ﹤0.01% 1071
2019
Q2 		$6K Hold
399
– – ﹤0.01% 1090
2019
Q1 		$6K Sell
399
-201
-34% -$2.31K ﹤0.01% 1075
2018
Q4 		$6K Buy
+600
New +$7.89K ﹤0.01% 1050

Other funds holding DRNA

CAM
Close Asset Management London, United Kingdom $3.69B AUM 21.62% 1-Year Est. Return

Daiwa Securities Group's DRNA Position: Q4 2021 in Review

Daiwa Securities Group sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 266 shares — an estimated $5K sold.

Daiwa Securities Group first reported a position in DRNA in Q4 2018 and held it in 12 quarters. The position peaked at $9K in Q4 2019. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.

  • Daiwa Securities Group reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
  • Daiwa Securities Group sold 266 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $5K.
  • Daiwa Securities Group first reported a position in Dicerna Pharmaceuticals, Inc. in Q4 2018 and held it in 12 quarters.
  • Daiwa Securities Group's Dicerna Pharmaceuticals, Inc. position peaked at $9K in Q4 2019.
  • 1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.

Based on Daiwa Securities Group's 13F filing for Q4 2021, filed 3 Feb 2022.